Developer of therapeutic antibodies designed to provide care against immuno-oncology targets. The company's technology leverages the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of antibody-derived therapeutics for the treatment of cancer, providing a larger number of cancer patients with the benefit of immunotherapy.
US - Pacific
Marketed, Phase III, Phase l or ll
1124 Columbia Street
Seattle, WA 98104
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.